Rocket Pharmaceuticals Net Income
| RCKT Stock | USD 3.24 0.04 1.25% |
As of the 11th of February 2026, Rocket Pharmaceuticals holds the Coefficient Of Variation of 10990.23, semi deviation of 3.22, and Risk Adjusted Performance of 0.0152. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Rocket Pharmaceuticals, as well as the relationship between them.
Analyzing historical trends in various income statement and balance sheet accounts from Rocket Pharmaceuticals' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Rocket Pharmaceuticals' valuation are summarized below:There are currently one hundred twenty trending fundamental ratios for Rocket Pharmaceuticals that can be evaluated and compared over time across competitors. All traders should check out Rocket Pharmaceuticals' recent fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 935.4 M in 2026. Enterprise Value is likely to drop to about 853 M in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -232.9 M | -221.2 M | |
| Net Loss | -232.9 M | -221.2 M | |
| Net Loss | -199.7 M | -189.7 M | |
| Net Loss | (2.46) | (2.58) | |
| Net Income Per E B T | 1.21 | 1.17 |
Rocket | Net Income | Build AI portfolio with Rocket Stock |
The evolution of Net Income for Rocket Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Rocket Pharmaceuticals compares to historical norms and industry peers.
Latest Rocket Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Rocket Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Rocket Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Rocket Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Rocket Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rocket Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (258.75 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Rocket Net Income Regression Statistics
| Arithmetic Mean | (107,614,072) | |
| Coefficient Of Variation | (90.85) | |
| Mean Deviation | 87,381,262 | |
| Median | (74,518,000) | |
| Standard Deviation | 97,771,872 | |
| Sample Variance | 9559.3T | |
| Range | 252.7M | |
| R-Value | (0.94) | |
| Mean Square Error | 1178.6T | |
| R-Squared | 0.88 | |
| Slope | (18,208,386) | |
| Total Sum of Squares | 152949.4T |
Rocket Net Income History
Other Fundumenentals of Rocket Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Rocket Pharmaceuticals Net Income component correlations
Rocket Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Rocket Pharmaceuticals is extremely important. It helps to project a fair market value of Rocket Stock properly, considering its historical fundamentals such as Net Income. Since Rocket Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Rocket Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Rocket Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Rocket introduce new products? Factors like these will boost the valuation of Rocket Pharmaceuticals. Anticipated expansion of Rocket directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Rocket Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Rocket Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Rocket Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Rocket Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between Rocket Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rocket Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Rocket Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Rocket Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Rocket Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Rocket Pharmaceuticals.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Rocket Pharmaceuticals on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Rocket Pharmaceuticals or generate 0.0% return on investment in Rocket Pharmaceuticals over 90 days. Rocket Pharmaceuticals is related to or competes with GeoVax Labs, BioLineRx, Tharimmune, Ainos, and Lipocine. Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that fo... More
Rocket Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Rocket Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Rocket Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.46 | |||
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 19.8 | |||
| Value At Risk | (4.96) | |||
| Potential Upside | 8.04 |
Rocket Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rocket Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Rocket Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Rocket Pharmaceuticals historical prices to predict the future Rocket Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0152 | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.37) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0168 |
Rocket Pharmaceuticals February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0152 | |||
| Market Risk Adjusted Performance | 0.0268 | |||
| Mean Deviation | 2.91 | |||
| Semi Deviation | 3.22 | |||
| Downside Deviation | 3.46 | |||
| Coefficient Of Variation | 10990.23 | |||
| Standard Deviation | 3.83 | |||
| Variance | 14.7 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.37) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0168 | |||
| Maximum Drawdown | 19.8 | |||
| Value At Risk | (4.96) | |||
| Potential Upside | 8.04 | |||
| Downside Variance | 11.97 | |||
| Semi Variance | 10.4 | |||
| Expected Short fall | (3.73) | |||
| Skewness | 0.3863 | |||
| Kurtosis | 0.5869 |
Rocket Pharmaceuticals Backtested Returns
Currently, Rocket Pharmaceuticals is relatively risky. Rocket Pharmaceuticals maintains Sharpe Ratio (i.e., Efficiency) of 0.0285, which implies the firm had a 0.0285 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Rocket Pharmaceuticals, which you can use to evaluate the volatility of the company. Please check Rocket Pharmaceuticals' Risk Adjusted Performance of 0.0152, coefficient of variation of 10990.23, and Semi Deviation of 3.22 to confirm if the risk estimate we provide is consistent with the expected return of 0.11%. Rocket Pharmaceuticals has a performance score of 2 on a scale of 0 to 100. The company holds a Beta of 1.48, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Rocket Pharmaceuticals will likely underperform. Rocket Pharmaceuticals right now holds a risk of 3.94%. Please check Rocket Pharmaceuticals value at risk, and the relationship between the jensen alpha and skewness , to decide if Rocket Pharmaceuticals will be following its historical price patterns.
Auto-correlation | -0.29 |
Weak reverse predictability
Rocket Pharmaceuticals has weak reverse predictability. Overlapping area represents the amount of predictability between Rocket Pharmaceuticals time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Rocket Pharmaceuticals price movement. The serial correlation of -0.29 indicates that nearly 29.0% of current Rocket Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.29 | |
| Spearman Rank Test | -0.44 | |
| Residual Average | 0.0 | |
| Price Variance | 0.05 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Rocket Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Rocket Pharmaceuticals reported net income of (258.75 Million). This is 175.82% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 145.32% higher than that of the company.
Rocket Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rocket Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rocket Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rocket Pharmaceuticals by comparing valuation metrics of similar companies.Rocket Pharmaceuticals is currently under evaluation in net income category among its peers.
Rocket Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Rocket Pharmaceuticals from analyzing Rocket Pharmaceuticals' financial statements. These drivers represent accounts that assess Rocket Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Rocket Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 1.4B | 1.3B | 2.5B | 1.2B | 1.1B | 935.4M | |
| Enterprise Value | 1.2B | 1.2B | 2.5B | 1.1B | 948.2M | 853.0M |
Rocket Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Rocket Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Rocket Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Rocket Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Rocket Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Rocket Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Rocket Pharmaceuticals' value.| Shares | Two Sigma Investments Llc | 2025-06-30 | 1.7 M | Prosight Management, Lp | 2025-06-30 | 1.6 M | Goldman Sachs Group Inc | 2025-06-30 | 1.6 M | Qube Research & Technologies | 2025-06-30 | 1.5 M | Two Sigma Advisers, Llc | 2025-06-30 | 1.5 M | Jpmorgan Chase & Co | 2025-06-30 | 1.2 M | The Toronto-dominion Bank | 2025-06-30 | 1.1 M | T. Rowe Price Associates, Inc. | 2025-06-30 | 1.1 M | D. E. Shaw & Co Lp | 2025-06-30 | 992.8 K | Rtw Investments, Llc | 2025-06-30 | 17.7 M | Maverick Capital Ltd | 2025-06-30 | 8.4 M |
Rocket Fundamentals
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 148.6 M | ||||
| Shares Outstanding | 108.22 M | ||||
| Shares Owned By Insiders | 3.68 % | ||||
| Shares Owned By Institutions | 91.08 % | ||||
| Number Of Shares Shorted | 13.39 M | ||||
| Price To Book | 1.10 X | ||||
| EBITDA | (247.49 M) | ||||
| Net Income | (258.75 M) | ||||
| Cash And Equivalents | 321.37 M | ||||
| Cash Per Share | 4.87 X | ||||
| Total Debt | 25.5 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 13.41 X | ||||
| Book Value Per Share | 2.90 X | ||||
| Cash Flow From Operations | (209.72 M) | ||||
| Short Ratio | 6.19 X | ||||
| Earnings Per Share | (2.28) X | ||||
| Price To Earnings To Growth | 0.03 X | ||||
| Target Price | 7.65 | ||||
| Number Of Employees | 299 | ||||
| Beta | 0.48 | ||||
| Market Capitalization | 350.64 M | ||||
| Total Asset | 527.7 M | ||||
| Retained Earnings | (1.22 B) | ||||
| Working Capital | 337.5 M | ||||
| Net Asset | 527.7 M |
About Rocket Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rocket Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rocket Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rocket Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rocket Stock Analysis
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.